HeartSciences Inc. (NASDAQ:HSCS) Short Interest Down 20.6% in December

HeartSciences Inc. (NASDAQ:HSCS) was the target of a significant decrease in short interest during the month of December. As of December 15th, there was short interest totaling 29,118 shares, a decrease of 20.6% from the November 30th total of 36,682 shares. Based on an average daily volume of 69,464 shares, the days-to-cover ratio is currently 0.4 days. Approximately 0.9% of the company’s stock are short sold. Approximately 0.9% of the company’s stock are short sold. Based on an average daily volume of 69,464 shares, the days-to-cover ratio is currently 0.4 days.

Analyst Ratings Changes

HSCS has been the topic of several analyst reports. Ascendiant Capital Markets boosted their price target on shares of HeartSciences from $9.00 to $9.20 and gave the stock a “buy” rating in a research report on Monday, December 22nd. Wall Street Zen upgraded HeartSciences from a “sell” rating to a “hold” rating in a report on Friday, October 3rd. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of HeartSciences in a research note on Monday, December 22nd. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $9.20.

HeartSciences Price Performance

Shares of HSCS opened at $3.17 on Tuesday. The company has a market cap of $10.08 million, a PE ratio of -0.46 and a beta of 2.57. The firm has a 50-day moving average of $2.78 and a 200-day moving average of $3.34. HeartSciences has a one year low of $2.01 and a one year high of $6.47.

HeartSciences (NASDAQ:HSCS) last issued its earnings results on Monday, December 15th. The company reported ($0.85) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.90) by $0.05. The firm had revenue of $2.42 million during the quarter, compared to analyst estimates of $0.00 million. Analysts expect that HeartSciences will post -10.01 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in HeartSciences stock. TFB Advisors LLC purchased a new stake in HeartSciences Inc. (NASDAQ:HSCS) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 29,740 shares of the company’s stock, valued at approximately $105,000. TFB Advisors LLC owned 1.12% of HeartSciences at the end of the most recent quarter. 17.24% of the stock is currently owned by institutional investors and hedge funds.

HeartSciences Company Profile

HeartSciences, Inc (NASDAQ: HSCS) is a medical device company focused on the development and commercialization of advanced, non‐invasive cardiac diagnostic technologies. The company’s flagship product, MyoVista, is a high‐fidelity electrocardiograph (ECG) designed to detect subtle changes in cardiac function that may indicate myocardial ischemia or left ventricular dysfunction. By leveraging high‐frequency wavelet analysis within the QRS complex, MyoVista provides clinicians with enhanced visualization and analytical capabilities that extend beyond those of standard ECG systems.

HeartSciences supports the MyoVista system with an integrated software suite that automates data analysis and report generation, facilitating seamless integration into existing clinical workflows.